Influx Healthtech share price today

Influx Healthtech Ltd's share price was ₹262.35 at the close on 4 November 2026. It has been rising for 69 weeks. That is 3.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹180 and ₹312, and at that close it sat 62% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Influx Healthtech Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row.

Over the last 1 year the share price moved +95% while the NIFTY 500 moved −7%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: number of shareholders up 27% in a year.

1. Number of shareholders up 27% in a year

   1,296 shareholders in the September 2026 quarter, against 1,022 a year earlier.

For January to March 2026 (the quarter ended 31 March 2026), Influx Healthtech reported revenue of ₹80.0 crore, up 40.4% from ₹57.0 crore a year earlier, and a profit of ₹11.0 crore, up 37.5% from ₹8.00 crore.

Influx Healthtech results: January to March 2026 against a year earlier

The next results, for April to June 2026, were due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them.

Influx Healthtech's management discussed these results on a call held on 22 May 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.

Influx Healthtech closed at ₹262.35 on 4 November 2026, up 36.0% from ₹192.90 a year earlier (7 November 2025). Its highest weekly close since June 2025 was ₹302.75 on 28 August 2026.

Influx Healthtech share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

78 weekly closes from 27 June 2025 to 4 November 2026.

4 Nov 2026: Influx Healthtech closed at ₹262.35, down 0.8% on the week and up 2.5% on the month. 22 May 2026: Influx Healthtech held its results call for January to March 2026. Management guided: FY27 revenue growth minimum 25-30% (prepared, conservative estimate, directional)

Earlier

• Results for January to March 2026: Revenue up 40.4% and profit up 37.5% on a year earlier.

Influx Healthtech has paid no dividend on the NSE since its first NSE close in our records (27 June 2025), the start of the period we checked.

No. Influx Healthtech Ltd paid out 0% of its profit as dividends in each of its last 5 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

On the call for January to March 2026, held on 22 May 2026, Influx Healthtech's management guided: FY27 revenue growth minimum 25-30% (prepared, conservative estimate, directional)

“When we start, we will be commissioning 2.5x of our current capacity, which can take us to 450-500 crores in a couple of years. This is our expectation. We will still have space if required. It is a dynamic industry, so if a new technology emerges, we have the space to react.”Dr. Munir Chandniwala, on the call for January to March 2026

What management guided

• New facility commissioning July-August 2026 with regulatory licensing process starting immediately (prepared, specific dates); Olahe Wellness similarly expected August 2026 licensing approval (prepared, specific)
• New facility FY27 revenue contribution ₹40-50 crores contingent on demand absorption (extracted, range); ₹450-500 crores FY29 goal (prepared, specific, multi-year)
• Operating margin FY27 20-22% (extracted, specific range) with profit margin 14-15% (prepared, specific); represents flat-to-accretive trajectory versus FY26's 20.3% operating profit and 14.0% profit despite higher revenue growth.
• Pet care capacity 25 tons/month within 2-3 months from current 16-18 tons (prepared, specific); export growth 10-15% annually with plus 5-7% on a year earlier incremental pursuit (prepared, directional)

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for January to March 2026, 22 May 2026.

When Influx Healthtech reports April to June 2026, these are the 4 checks that show whether the story is still on course. First: New facility commissioning and regulatory licensing approval pace for July-August 2026 - critical credibility checkpoint validating ₹450-500 crore FY29 goal and growth algorithm sustainability.

Influx Healthtech is on one of our India lists: Pharma stocks.

Influx Healthtech Ltd earned ₹11.0 Cr of net profit in the Mar 2026 quarter, +37.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹21.0 Cr. That is 13.8% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹21.0 Cr (+61.5% on the year before).

Influx Healthtech Ltd reported ₹80.0 Cr of revenue in the Mar 2026 quarter, +40.4% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. The last full year, FY26, came in at ₹147 Cr.

Revenue is everything the company billed its customers in the period.

A growth rate over several years is not shown, because there are too few years of figures to work one out properly.

FY26 revenue was ₹147 Cr, +40.0% on the year before.

Influx Healthtech Ltd's operating margin was 19.0% in the Mar 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 11.0% and 20.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 44% of Influx Healthtech Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹4.0 Cr of operating cash against ₹21.0 Cr of profit. After ₹16.0 Cr of spending on assets, free cash was −₹12.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 44% of profit came in as cash: the cash cycle got 74 days longer between FY22 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 74 days longer. The next section looks at where the cash is stuck.

Influx Healthtech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 64 days in FY26, up from −10 days in FY22. It spent ₹34.0 Cr on assets over the last 3 years. Customers take 84 days to pay, and stock sits for 98 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹147 Cr, each day of that cycle ties up about ₹0.4 Cr, so roughly ₹26.0 Cr is tied up in the business at any time.

FY26: customers took 84 days to pay and stock sat for 98 days, about 3.2 months of sales sitting as stock, for a full cycle of 64 days, longer than FY22's −10.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 98 days. Customers pay about 84 days after that. Suppliers are paid at 118 days. Together that makes the 64-day cycle.

Spending on assets: ₹34.0 Cr over the last 3 years, against ₹9.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Influx Healthtech Ltd's P/E is 31.8×, near the high end of its own history: higher than 77% of past readings. Its usual P/E (the middle reading) is 26.8×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +21.3% while the price moved +36.0%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 50% on reported income across 3 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Influx Healthtech Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Influx Healthtech Ltd earned a ROCE of 38% in FY26. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 14.3% net margin and 1.19× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 14.3% net margin × 1.19× asset turnover × 1.23× leverage (assets divided by equity) ≈ 20.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 50% on reported income across 3 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Influx Healthtech Ltd had ₹0.0 Cr of borrowings against ₹101 Cr of equity in FY26, so its debt is 0.00× its equity. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr. Over the last 3 of those years it spent ₹34.0 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

The spending on assets is being paid for from cash, not new debt.

No group of Influx Healthtech Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

For Influx Healthtech Ltd, the Z-score is left out, because it comes from the second data source we could not check, and a safety score is not worth showing when two sources disagree. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

49.7 out of 100, rank 41 of 44 in Pharma - Formulators, with 42% of the evidence available. It is provisional, so it is ranked below companies with full evidence.

Influx Healthtech Ltd scores 49.7 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 41. Some evidence is missing, so the score is pulled toward the middle on purpose.

The four parts add up to the total exactly: 16.2 + 17.9 + 10.2 + 5.4 = 49.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Influx Healthtech ranks 41 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 49.7 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - Formulators, all 44 compared on one page.

Influx Healthtech is the 43rd largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Bafna Pharmaceuticals, Bajaj Healthcare, Lincoln Pharmaceuticals, Zim Laboratories and Kilitch Drugs (India). Just below it: Syncom Healthcare.

Pharma - Formulators companies close in size

38. Bafna Pharmaceuticals Ltd ₹1,060 crore
39. Bajaj Healthcare Ltd ₹1,031 crore
40. Lincoln Pharmaceuticals Ltd ₹1,000 crore
41. Zim Laboratories Ltd ₹731 crore
42. Kilitch Drugs (India) Ltd ₹704 crore
43. Influx Healthtech Ltd ₹612 crore
44. Syncom Healthcare Ltd ₹17 crore

All 44 Pharma - Formulators companies, largest first

Companies close in size in other industries

1888. Rama Steel Tubes Ltd ₹614 crore · Steel - Tubes/Pipes
1889. India Power Corporation Ltd ₹612 crore · Power - Generation/Distribution
1890. Influx Healthtech Ltd ₹612 crore
1891. Coffee Day Enterprises Ltd ₹611 crore · Quick Service Restaurant - QSR
1892. Hardwyn India Ltd ₹610 crore · Trading

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.